Skip to main content

Table 3 Gene mutations and clinical characteristics

From: Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia

  wt vs mut P value
TET2    
Age(>65y), % 36.2 61.2 0.005
BM blasts(>10 %), % 37.8 17 0.008
WBC(109/L), median, range 12.96(3.05–98.03) 16.00(3.01–70.50) 0.961
ANC(109/L), median, range 5.83(0.30–66.91) 8.78(1.12–28.64) 0.617
AMC(109/L), median, range 3.06(1.02–18.00) 3.13(1.06–17.63) 0.874
Hb(g/L), median, range 91.0(43.0–158.0) 88.0(43.0–166.0) 0.409
PLT(109/L), median, range 68.0(3.8–895.0) 87.0(9.0–1001.0) 0.866
SRSF2    
Age(>65y), % 24.2 64.1 0.000
BM blasts(>10 %), % 33 26.2 0.361
WBC(109/L), median, range 11.47(3.01–98.03) 21.35(5.06–70.50) 0.007
ANC(109/L), median, range 4.92(0.30–66.91) 13.55(1.75–33.90) 0.008
AMC(109/L), median, range 2.29(1.02–18.00) 3.72(1.16–17.63) 0.004
Hb(g/L), median, range 84.0(43.0–166.0) 106.5(56.0–166.0) 0.000
PLT(109/L), median, range 67.5(3.8–895.0) 100.0(9.0–1001.0) 0.392
ASXL1    
Age(>65y), % 52.3 53.8 0.863
BM blasts(>10 %), % 28.8 38.8 0.393
WBC(109/L), median, range 11.47(3.01–92.40) 20.10(3.62–98.03)) 0.123
ANC(109/L), median, range 5.17(0.30–66.91) 10.45(0.46–56.66) 0.052
AMC(109/L), median, range 2.52(1.06–18.00) 3.20(1.02–14.82) 0.082
Hb(g/L), median, range 92.0(44.0–166.0) 87.5(43.0–158.0) 0.187
PLT(109/L), median, range 69.0(6.6–1001.0) 90.5(3.8–633.0) 0.487
SETBP1    
Age(>65y), % 57.7 52.1 0.605
BM blasts(>10 %), % 29.4 38.5 0.415
WBC (109/L), median, range 12.69(3.01–98.03) 20.46(6.60–49.10) 0.173
ANC (109/L), median, range 5.50(0.30–66.91) 11.75(2.56–33.90) 0.079
AMC (109/L), median, range 2.62(1.06–18.00) 3.25(1.02–11.03) 0.413
Hb(g/L), median, range 88.5(43.0–166.0) 90.5(52.0–137.0) 0.622
PLT(109/L), median, range 74.25(5.0–1001.0) 118.5(3.8–534.0) 0.337